These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31253599)

  • 1. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
    Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
    Jones RB; Hiemstra TF; Ballarin J; Blockmans DE; Brogan P; Bruchfeld A; Cid MC; Dahlsveen K; de Zoysa J; Espigol-Frigolé G; Lanyon P; Peh CA; Tesar V; Vaglio A; Walsh M; Walsh D; Walters G; Harper L; Jayne D;
    Ann Rheum Dis; 2019 Mar; 78(3):399-405. PubMed ID: 30612116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.
    Kuzuya K; Morita T; Kumanogoh A
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.
    Hiemstra TF; Walsh M; Mahr A; Savage CO; de Groot K; Harper L; Hauser T; Neumann I; Tesar V; Wissing KM; Pagnoux C; Schmitt W; Jayne DR;
    JAMA; 2010 Dec; 304(21):2381-8. PubMed ID: 21060104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
    Morgan MD; Szeto M; Walsh M; Jayne D; Westman K; Rasmussen N; Hiemstra TF; Flossmann O; Berden A; Höglund P; Harper L;
    Arthritis Res Ther; 2017 Jun; 19(1):129. PubMed ID: 28592297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide.
    Stassen PM; Tervaert JW; Stegeman CA
    Ann Rheum Dis; 2007 Jun; 66(6):798-802. PubMed ID: 17179175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
    Hu W; Liu C; Xie H; Chen H; Liu Z; Li L
    Nephrol Dial Transplant; 2008 Apr; 23(4):1307-12. PubMed ID: 18065810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
    Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
    PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Strategies in ANCA-Associated Vasculitis.
    Emejuaiwe N
    Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
    Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
    Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of mycophenolate mofetil versus cyclophosphamide in patients with active antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of randomized trials.
    Song GG; Lee YH
    Z Rheumatol; 2021 Jun; 80(5):425-431. PubMed ID: 32337635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis.
    Berti A; Alsawas M; Jawaid T; Prokop LJ; Lee JM; Jeong GH; Quintana LF; Moiseev S; Vaglio A; Tesar V; Geetha D; Shin JIL; Kronbichler A
    Nephrol Dial Transplant; 2022 Oct; 37(11):2190-2200. PubMed ID: 34910216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital.
    Draibe J; Poveda R; Fulladosa X; Vidaller A; Zulberti C; Gomà M; Pujol R; Ripoll È; Torras J; Grinyó JM
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i132-7. PubMed ID: 25805744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of ANCA associated vasculitis.
    Wallace ZS; Miloslavsky EM
    BMJ; 2020 Mar; 368():m421. PubMed ID: 32188597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
    Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D;
    Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.
    Liu LL; Jiang Y; Wang LN; Yao L; Li ZL
    Drugs; 2012 Jul; 72(11):1521-33. PubMed ID: 22818016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    Faurschou M; Westman K; Rasmussen N; de Groot K; Flossmann O; Höglund P; Jayne DR;
    Arthritis Rheum; 2012 Oct; 64(10):3472-7. PubMed ID: 22614882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.